Posts classified under: Affinity Groups

Keith Vossel

Keith Vossel’s laboratory studies mechanisms and novel treatments for seizures and associated memory loss in Alzheimer’s disease. Investigations include cell and molecular, neural network, and behavior relationships in mouse models of Alzheimer’s disease and related dementias, and bridges bench discoveries with human clinical trials.

Recent Publications

  • Johnson, EL, Krauss GL, Kucharska-Newton A, Albert MS, Brandt J, Walker KA, Yasar S, Knopman DS, Vossel K, Gottesman RF. Dementia in late-onset epilepsy: the Atherosclerosis Risk in Communities study. Neurology 2020. In Press.
  • Peters ST, Fahrenkopf A, Choquette JM, Vermilyea S, Lee MK, Vossel K. Ablating tau reduces hyperexcitability and moderates electroencephalographic slowing in transgenic mice expressing A53T human α-synuclein. Frontiers in Neurology 2020, 11:563. doi: 10.3389/fneur.2020.00563.
  • Ranasinghe KG, Cha J, Hinkley LB, Beagle AJ, Jagust W, Miller BL, Rankin KP, Rabinovici GD, Vossel KA, Nagarajan SS. Neurophysiological signatures in Alzheimer’s disease are distinctly associated with tau, amyloid-beta accumulation, and cognitive decline. Science Translational Medicine 2020. doi: 10.1126/scitranslmed.aaz4069.
  • Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL. Epileptic activity in Alzheimer’s disease: causes and clinical relevance. The Lancet Neurology 2017, 16:311-322.
  • Beagle AJ, Darwish SM, Ranasinghe KG, La AL, Karageorgiou E, Vossel KA. Relative incidence of seizures and myoclonus in Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia. Journal of Alzheimer’s Disease 2017, 60:211-223. doi: 10.3233/JAD-170031.
  • Vossel KA, Ranasinghe KG, Beagle AJ, Mizuiri D, Honma SM, Dowling AF, Darwish SM, Barnes DE, Mantle M, Roberson ED, Miller BL, Garcia PA, Kirsch HE, Mucke L, Nagarajan SS. Incidence and impact of subclinical epileptiform activity in Alzheimer’s disease. Annals of Neurology 2016, 80:858-870. doi: 10.1002/ana.24794.
  • Vossel KA, Xu JC, Fomenko V, Miyamoto T, Suberbielle E, Knox JA, Ho K, Yu G, Mucke L. Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β. The Journal of Cell Biology 2015, 209:419-433. doi: 10.1083/jcb.201407065.
  • Ranasinghe KG, Hinkley LB, Beagle AJ, Mizuiri D, Dowling AF, Honma SM, Finucane MM, Scherling C, Miller BL, Nagarajan SS, Vossel KA. Regional functional connectivity predicts distinct cognitive impairments in Alzheimer’s disease spectrum. NeuroImage Clinical 2014, 5:385–395. doi: 10.1016/j.nicl.2014.07.006.
  • Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurology 2013, 70:1158-66. doi: 10.1001/jamaneurol.2013.136.
  • Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L. Tau reduction prevents Aβ-induced defects in axonal transport. Science 2010, 330:198. doi: 10.1126/science.1194653.